Literature DB >> 11560493

Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.

P Hammarström1, X Jiang, S Deechongkit, J W Kelly.   

Abstract

The balance between stabilizing forces and the localized electrostatic repulsions destabilizing the transthyretin (TTR) tetramer is tunable via anion shielding. The two symmetrical anion interaction sites in TTR are comprised of residues Lys15 and Lys15' from opposing subunits on the periphery of the two thyroxine binding sites. These epsilon-ammonium groups repel one another and destabilize the tetramer, unless an appropriate anion is present, which stabilizes the tetramer. Chaotrope denaturation of TTR exhibits unusual behavior in that urea appears to be a stronger denaturant than GdmCl (guanidinium chloride), even though GdmCl is typically twice as powerful as a denaturant. The shift in the midpoint of the urea denaturation curve to higher concentrations as well as the increase in the mole fraction of tetramer that is highly resistant to denaturation with increasing KCl concentration provides strong evidence that anion shielding stabilizes the TTR tetramer. A consequence of tetramer stabilization is folding hysteresis, because the high GdmCl concentrations required to denature the anion-stabilized tetramer do not allow refolding of the unfolded monomers. The formation of amyloid fibrils by TTR requires that its normal tetrameric structure dissociate to alternatively folded monomers, a process mediated by acidification (pH 5-4). This process is inhibited by Cl(-) ions in a concentration-dependent fashion. Chloride ion may not be the relevant physiological TTR stability modulator, but it is the main focus of these studies explaining the hysteresis observed in the denaturation and refolding studies with GdmCl.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560493     DOI: 10.1021/bi010673+

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  Tracking the heterogeneous distribution of amyloid spherulites and their population balance with free fibrils.

Authors:  V Foderà; A M Donald
Journal:  Eur Phys J E Soft Matter       Date:  2010-11-04       Impact factor: 1.890

2.  A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.

Authors:  Sungwook Choi; Derrick Sek Tong Ong; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-10-21       Impact factor: 15.419

3.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

4.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.

Authors:  X Jiang; J N Buxbaum; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

5.  Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.

Authors:  Lei Zhao; Joel N Buxbaum; Natàlia Reixach
Journal:  Biochemistry       Date:  2013-03-04       Impact factor: 3.162

6.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.

Authors:  Elena S Klimtchuk; Tatiana Prokaeva; Nicholas M Frame; Hassan A Abdullahi; Brian Spencer; Surendra Dasari; Haili Cui; John L Berk; Paul J Kurtin; Lawreen H Connors; Olga Gursky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

Review 7.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 8.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

9.  Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.

Authors:  Sungwook Choi; Stephen Connelly; Natàlia Reixach; Ian A Wilson; Jeffery W Kelly
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

10.  Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors.

Authors:  Teresa Mairal; Joan Nieto; Marta Pinto; Maria Rosário Almeida; Luis Gales; Alfredo Ballesteros; José Barluenga; Juan J Pérez; Jesús T Vázquez; Nuria B Centeno; Maria Joao Saraiva; Ana M Damas; Antoni Planas; Gemma Arsequell; Gregorio Valencia
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.